## Anti-CD20 therapy in multiple sclerosis - Clinical and paraclinical outcomes

© Alexander Juto, 2021 ISBN 978-91-8016-183-1

| Location | Error | Printed version | Correction |
| :---: | :---: | :---: | :---: |
| p. 11 |  |  |  |
| eighth line | wrong no. of patients | 349 patients | 439 patients |
| ninth line | wrong dosing schedule | given 1000 mg RTX or placebo every six months | given two doses of 1000 mg RTX or placebo every six months |
| p. 16, section 2.3.1, ninth line | drug and reference missing | alemtuzumab and mitoxantrone are classified as induction therapies ${ }^{129}$ | alemtuzumab, mitoxantrone and cladribine are classified as induction therapies ${ }^{126,129}$ |
| p. 18, section 2.4.4, first line | wrong reference | associated with development of ADA ${ }^{90,145}$ | associated with development of ADA ${ }^{90,99}$ |
| p. 25 <br> section 3.2, <br> first bullet <br> point | wrong drug switch reason | due to lack of effect or AEs on | due to breakthrough disease on |
| section 3.2, third bullet point | wrong disease term | ADAs against RTX among RRMS patients | ADAs against RTX among MS patients |
| p. 27, second line | wrong disease term | 101 patients with SPMS | 101 patients with progressive MS |
| p. 28, second to last line | partly missing reference values and units | of $<0.01 \times 10^{9}$ cells/L was regarded as complete B -cell depletion, 0.01 to $<0.09 \times 10^{9}$ cells/L as incomplete B-cell depletion and $\geq$ as normalised B-cell levels | of $<0.01 \times 10^{9}$ cells $/ \mathrm{L}$ was regarded as complete B-cell depletion, 0.01 to $<0.09 \times 10^{9}$ cells/L as incomplete B-cell depletion and $\geq 0.09 \times 10^{9}$ cells/L as normalised B-cell level |
| p. 30, section 4.3.4, eighth line | wrong word | dividing by the cortical intracranial volume | dividing by the total intracranial volume |
| p. 40, section 6.1.2, second to last line | missing words | terminating RTX treatment described | terminating RTX treatment due to AEs described |
| p. 41, section 6.1.3, last line | wrong disease term, missing reference | RTX in RRMS ${ }^{90,91,194}$ and in other diseases. ${ }^{197,198}$ | RTX in MS ${ }^{90,91,194}$ and in other diseases. ${ }^{196,197,198}$ |
| Study IV, methods MRI, thirteenth line | wrong word | divided by the estimated cortical intracranial volume | divided by the estimated total intracranial volume |

The correct version of acknowledgements on pages 51-52 is as follows:

## 9. ACKNOWLEDGEMENTS

This work is the result of great support from my beloved family as well as from the many gifted and devoted researchers whom I have collaborated with during my PhD studies. In particular, I would like to thank:

Professor Fredrik Piehl, my main supervisor, for giving me the opportunity to conduct doctoral studies as well as all the generous support and guidance throughout these years. It has been a true pleasure working with you and I am grateful for the great introduction to research that you have given me.

Tobias Granberg, my co-tutor, for your inspiring nature as a talented and driven researcher and radiologist. Working with you meant clear-cut and constructive tutoring, always delivered in an encouraging manner.

Thomas Frisell, my co-tutor, for your epidemiological and statistical skills and your patience. Despite my lack of knowledge in statistics, you succeeded in guiding me through these matters so that I eventually understood what I was doing.

Faiez Al Nimer, my co-author, for your unconditional and extensive support throughout the work with Study II. Your contribution was crucial and I am deeply grateful for that.

Nicky Dunn, my co-first author for a great collaboration during our study on anti-RTX antibodies.
Katharina Fink, for your valuable comments as a co-author.
Anna Fogdell-Hahn, for your advanced knowledge in immunology that you generously shared with me and your comments as co-author.

Ali Manouchehrinia, for the great support with statistical analyses when I was just in the very beginning of my PhD studies.

Jonatan Salzer, my co-author, for your valuable contribution during the work on Study I.
Malin Boremalm, my co-first author, for our fruitful collaboration during the work on Study I, which we managed to carry out despite the geographical distance between us.

Magnus Andersson, for giving me a position as resident physician in neurology at the Neurology Department at Karolinska University Hospital in 2016.

Eva Lindström, for being a mentor during my doctoral studies.
Russell Ouellette, for the generous support and guidance on how to export MRI data.
NEURO Sweden (Swedish: Neuroförbundet) through Neurofonden, for financial support during my time as a doctoral student.

All my colleagues (former and present) at the Neurology Department: Christina Sjöstrand, Lou Brundin, Albert Hietala, Henrik Matell, Gylfi Thormar, Einar Eriksson, Erik Lundström, Mathias Sundgren, Maria Bäärnhielm, Olafur Sveinsson, Ellen Iacobaeus, Anders Johansson, Giuseppe Stragliotto, Tiago Moreira, Niaz Ahmed, Michael Mazya, Malin

Säflund, Anna Steinberg, Charith Cooray, Magnus Thorén, Anna Sundholm, Boris Keselman, Anne Zachau, Sofia Hylin, Theresa Wangerid, Vasilios Stenimahitis, Per Lindström, Kosta Kostulas, Snjolaug Arnardottir, Eric Thelin, Anne Eriksson-Dufva, Sebastian Thams, Rose-Marie Noori, Stanislav Beniaminov, Anna Björck Mehr, Lisa Gordon, Karin Wirdefeldt, Raana Shafiei, Sara Melin, Karin Olsson and Dagur Jonsson.

My sisters Björg, Linda and Nicki and brother Kalle and their families.
My parents-in-law, Kicki and Staffan for all your support.
My parents, Monica and Jan-Erik for everything.
My darling son Wilhelm, born when I started my PhD studies. During these years, you have been a source of energy and inspiration as well as a lot of joy.

My beloved daughter Hilma, born during the final year of my doctoral education. You have brought so much happiness to my life and boosted my motivation by simply being you.

Last but not least, my dear wife Anna who has supported me in so many ways during these years. Without you, this would never have been possible.

